Pau D'arco for Anti-Inflammatory

Research suggests that pau d'arco may possess anti-inflammatory and pain-relieving properties, based on a small body of preclinical evidence. A 2001 rodent study found that an oral aqueous extract of Tabebuia avellanedae reduced pain responses and modestly inhibited inflammation-induced swelling, with findings pointing to adenosine signaling rather than opioid pathways as a possible mechanism. A more recent 2025 laboratory and pilot animal study found that pau d'arco, used as part of a multi-herb combination, reduced the inflammatory marker IL-8 in human cell lines and supported wound healing in horses, though isolating pau d'arco's specific contribution from the other herbs in that blend is difficult. Both studies are preclinical in nature — relying on animal models and cell cultures rather than human clinical trials — which means the available evidence, while directionally supportive, remains limited and cannot be directly applied to human health outcomes.